Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds

In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences

(2009) M. Vermeersch et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure−Activity Study of Pentamidine Analogues as Antiprotozoal Agents

(2009) Svetlana M. Bakunova et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen

(2009) Elizabeth R. Sharlow et al.   PLoS Neglected Tropical Diseases

Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials

(2008) Nashira Campos Vieira et al.   BIOMEDICINE & PHARMACOTHERAPY

Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda

(2008) J. H Kolaczinski et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Paromomycin: Uptake and resistance in Leishmania donovani

(2008) Anupam Jhingran et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

Asymmetries of Poverty: Why Global Burden of Disease Valuations Underestimate the Burden of Neglected Tropical Diseases

(2008) Charles H. King et al.   PLoS Neglected Tropical Diseases